Dimensional Fund Advisors LP Sells 1,196 Shares of Cara Therapeutics, Inc. (CARA)

Dimensional Fund Advisors LP trimmed its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 0.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 206,754 shares of the biopharmaceutical company’s stock after selling 1,196 shares during the quarter. Dimensional Fund Advisors LP owned 0.64% of Cara Therapeutics worth $3,182,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Teachers Advisors LLC raised its position in Cara Therapeutics by 18.1% in the 1st quarter. Teachers Advisors LLC now owns 39,418 shares of the biopharmaceutical company’s stock worth $725,000 after purchasing an additional 6,028 shares during the period. Vanguard Group Inc. raised its position in Cara Therapeutics by 20.0% in the 1st quarter. Vanguard Group Inc. now owns 943,627 shares of the biopharmaceutical company’s stock worth $17,353,000 after purchasing an additional 156,958 shares during the period. Geode Capital Management LLC raised its position in Cara Therapeutics by 5.0% in the 1st quarter. Geode Capital Management LLC now owns 186,106 shares of the biopharmaceutical company’s stock worth $3,422,000 after purchasing an additional 8,793 shares during the period. UBS Group AG raised its position in Cara Therapeutics by 16.9% in the 1st quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 1,528 shares during the period. Finally, Morgan Stanley raised its position in Cara Therapeutics by 360.3% in the 1st quarter. Morgan Stanley now owns 332,606 shares of the biopharmaceutical company’s stock worth $6,117,000 after purchasing an additional 260,344 shares during the period. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Cara Therapeutics, Inc. (CARA) opened at $12.39 on Monday. Cara Therapeutics, Inc. has a 1 year low of $8.61 and a 1 year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.03). During the same period last year, the firm earned ($0.42) EPS. research analysts predict that Cara Therapeutics, Inc. will post -1.84 earnings per share for the current year.

In other news, CEO Derek T. Chalmers sold 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total transaction of $202,560.00. Following the transaction, the chief executive officer now directly owns 1,066,292 shares of the company’s stock, valued at $13,499,256.72. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.70% of the company’s stock.

A number of analysts recently weighed in on CARA shares. CIBC reduced their price objective on shares of Cara Therapeutics from $26.00 to $24.00 in a research report on Tuesday, November 7th. Zacks Investment Research raised shares of Cara Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, August 30th. Piper Jaffray Companies set a $27.00 price objective on shares of Cara Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 5th. Canaccord Genuity set a $25.00 price objective on shares of Cara Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $25.17.

COPYRIGHT VIOLATION WARNING: “Dimensional Fund Advisors LP Sells 1,196 Shares of Cara Therapeutics, Inc. (CARA)” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/27/dimensional-fund-advisors-lp-sells-1196-shares-of-cara-therapeutics-inc-cara.html.

Cara Therapeutics Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply